Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Neurology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Alzheimer's Disease Clinical Trials

A listing of Alzheimer's Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (140) clinical trials

The MISSION-AD study is investigating the efficacy and safety of an investigational drug on symptoms of cognitive decline in individuals with mild cognitive impairment or early Alzheimer's disease. The study drug is a tablet which is taken by mouth once per day. The study will last approximately two years. Eligibility ...

Phase N/A

The purpose of this study is to find out if a study drug is safe and effective in the treatment of agitation caused by dementia. Volunteers will receive compensations up to $80.00 per completed visit, for their overall participation in this study to cover their time and travel. Volunteers will ...

Study Description: CREAD2 is a Phase 3 study investigating the effect of an investigational drug in the form of an infusion on Alzheimer's disease progression in individuals with prodromal to mild Alzheimer's disease. The study drug, crenezumab, is a monoclonal antibody that targets amyloid-beta proteins in the brain. The study ...

Phase

The primary objective of this study is to determine whether treatment with an oral investigational drug can slow cognitive decline compared with placebo treatment in individuals who are asymptomatic but at high risk for Alzheimer's disease. Asymptomatic means that the individual is not currently experiencing any symptoms of memory loss ...

Phase

A Study to Investigate the Regional Brain Kinetics of Brain Drug Transporters Using P-glycoprotein and Breast Cancer Resistance Protein Substrates and by Using the Positron Emission Tomography Ligand 11C-JNJ-63779586 in the Human Brain

The purpose of this study is to investigate the total body biodistribution and radiation dosimetry of 11C-JNJ-63779586 by Positron Emission Tomography (PET) in healthy young adult males (Part A); to estimate and compare the uptake, distribution, and clearance of 11C-JNJ-63779586 in the brain by PET between mild Alzheimer Disease (AD) ...

Phase

Effect of Low Dose Radiotherapy on Brain Amyloidosis in the Treatment of Alzheimer's Disease

Alzheimer's Disease (AD) is the most frequent neurodegenerative disease associated with dementia, with a constantly increasing prevalence associated with an aging population. Amyloid deposition is considered the first molecular event occurring in AD: as already showed in an animal model, a low-dose radiotherapy (RT) course is capable of reducing AD-associated ...

Phase N/A

Salsalate in Patients Mild to Moderate Alzheimer's Disease

This is a Phase 1b, 12-month, randomized, double-blind, placebo-controlled study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of salsalate in patients with mild to moderate AD. Approximately 40 subjects will be randomized 1:1 to placebo or active. All study drugs will be administered orally bid [two placebo tablets ...

Phase

Impact of Controlling Vascular Risk Factors on the Progression of Alzheimer's Disease

It is not currently known whether the optimum treatment of VRFs influences the progression and prognosis of Alzheimer's disease. Our starting hypothesis is that VRF control in Alzheimer's patients is associated with slower cognitive decline, less intense loss of personnel independence and fewer adverse events over the course of the ...

Phase N/A

Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation

Patients will be screened at Intermountain Medical Center and at Intermountain-affiliated anticoagulation clinics in the Salt Lake City region. Patients with non-valvular atrial fibrillation will be considered for study. After written informed consent is obtained, subjects who meet eligibility criteria will be randomized 1:1 to 2 treatment arms: Group 1: ...

Phase

Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION)

This study is a Phase 2, randomized, placebo controlled, dose ranging study of piromelatine (5, 20, and 50 mg daily for 6 months) versus placebo to determine an effective dose based on efficacy (cognitive performance), safety and tolerability in patients with mild dementia due to AD.

Phase